For years, many have turned to a daily aspirin as a potential shield against colorectal cancer, hoping to proactively reduce their risk of this common and often deadly disease. But a major recent review of existing research suggests that for most people, that practice offers little benefit and carries real, immediate risks. The analysis, published by Cochrane, a globally recognized network of researchers, finds that daily aspirin use doesn’t reliably prevent bowel cancer and significantly increases the chance of serious bleeding.
Colorectal cancer, affecting the colon or rectum, remains a significant public health concern, ranking among the most frequently diagnosed cancers worldwide. According to the American Cancer Society, an estimated 153,020 new cases of colorectal cancer will be diagnosed in the United States in 2024. Prevention strategies typically center around lifestyle factors – a healthy diet, regular exercise and routine screening tests like colonoscopies – but recent years have seen growing interest in whether readily available medications could also play a role.
The Cochrane review, which analyzed data from 10 randomized controlled trials encompassing over 124,000 participants, focused specifically on aspirin. Researchers at West China Hospital of Sichuan University in China sought to determine whether aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) could lower the risk of colorectal cancer or its precursor, precancerous polyps known as adenomas, in individuals at average risk. Notably, they found insufficient evidence to evaluate the effects of other NSAIDs like ibuprofen, limiting their conclusions to aspirin alone.
Limited Protection, Especially in the Short Term
The review’s findings indicate that aspirin likely provides no significant reduction in the risk of developing bowel cancer within the first five to 15 years of use. While some studies hinted at a possible protective effect after more than 10-15 years, the researchers emphasized that the certainty of this evidence is exceptionally low. This uncertainty stems from the nature of the data, which largely came from observational follow-up periods after the initial trials concluded. During these follow-up phases, participants may have independently started or stopped taking aspirin, or begun other treatments, introducing potential biases that complicate interpretation.
“While the idea of aspirin preventing bowel cancer in the long run is intriguing, our analysis shows that this benefit is not guaranteed and comes with immediate risks,” explained lead author Dr. Zhaolun Cai. This highlights a crucial point: any potential long-term benefit remains speculative and is far from a certainty.
The Immediate Risk of Bleeding
Perhaps the most concerning finding of the review is the clear and immediate risk associated with daily aspirin use: an increased likelihood of serious bleeding. The researchers found strong evidence that aspirin elevates the risk of extracranial hemorrhage – bleeding outside the brain – and likely increases the risk of hemorrhagic stroke, a potentially devastating type of stroke caused by bleeding in the brain.
Even low-dose, or “baby,” aspirin carries this risk, and the danger increases with higher doses. Older adults and individuals with a history of ulcers or bleeding disorders are particularly vulnerable. This immediate risk must be carefully weighed against any potential, and uncertain, long-term cancer benefits, the authors stress.
“My biggest worry is that people might assume that taking an aspirin today will protect them from cancer tomorrow,” said senior author Dr. Bo Zhang. “In reality, any potential preventive effect takes over a decade to appear, if it appears at all, while the bleeding risk begins immediately.”
Aspirin’s Role in High-Risk Groups
It’s important to note that previous research has suggested aspirin may offer benefits for specific high-risk groups, such as individuals with inherited conditions like Lynch syndrome, which significantly increases the risk of colorectal cancer. However, this Cochrane review specifically focused on people at average risk, and the evidence for a protective effect in this population remains highly uncertain.
The authors strongly advise against initiating aspirin therapy solely for cancer prevention without first discussing individual bleeding risks with a healthcare professional. “This review reinforces that we must move away from a one-size-fits-all approach,” stated Dr. Dan Cao, another senior author. “Widespread aspirin use in the general population simply isn’t supported by the evidence. The future lies in precision prevention – using molecular markers and individual risk profiles to identify who might benefit most and who is most at risk.”
The researchers emphasize that the relationship between aspirin and cancer prevention is complex and dynamic, with the balance between potential benefits and harms shifting over time. As Dr. Zhang concluded, “Our rigorous analysis of the highest-quality trials reveals that the ‘aspirin for cancer prevention’ story is more complex than a simple ‘yes or no.’ The current evidence does not support a blanket recommendation for aspirin use purely to prevent bowel cancer.”
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The debate surrounding aspirin’s role in cancer prevention is ongoing. Researchers continue to investigate potential benefits and risks, and future studies may refine our understanding. The next major update from Cochrane on this topic is expected in late 2027, following the completion of several ongoing long-term studies. For now, the message is clear: don’t start taking aspirin with the expectation of preventing colorectal cancer without a thorough discussion with your doctor.
What are your thoughts on this new research? Share your comments below, and please share this article with anyone who may be considering daily aspirin for cancer prevention.
